Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 2/20 | 0.65 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.65 |
| ▸ | ACE | P12821 | 5/20 | 0.63 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.62 |
| ▸ | CTSG | P08311 | 1/20 | 0.59 |
| ▸ | CMA1 | P23946 | 1/20 | 0.59 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.59 |
| ▸ | MME | P08473 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.56 |
| ▸ | CDC25B | P30305 | 1/20 | 0.56 |
| ▸ | FAAH | O00519 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4153101 | 1.00 | ITGB3 (0.65) | ITGB3ITGA2BACEPIN1CTSG | |
| SCHEMBL4153095 | 1.00 | ITGB3 (0.65) | ITGB3ITGA2BACEPIN1CTSG | |
| SCHEMBL4147924 | 0.93 | ITGB3 (0.62) | ITGB3ITGA2BACEPIN1NAALAD2 | |
| SCHEMBL4147413 | 0.93 | ITGB3 (0.62) | ITGB3ITGA2BACEPIN1NAALAD2 | |
| SCHEMBL4147417 | 0.93 | ITGB3 (0.62) | ITGB3ITGA2BACEPIN1NAALAD2 | |
| SCHEMBL4147927 | 0.93 | ITGB3 (0.62) | ITGB3ITGA2BACEPIN1NAALAD2 | |
| SCHEMBL9440322 | 0.91 | ITGB3 (0.61) | ITGB3ITGA2BACEPIN1CTSG | |
| SCHEMBL9440326 | 0.91 | ITGB3 (0.61) | ITGB3ITGA2BACEPIN1CTSG | |
| SCHEMBL10722448 | 0.90 | CTSG (0.68) | ITGB3ITGA2BACEPIN1CTSG | |
| SCHEMBL21391851 | 0.88 | ACE (0.55) | ITGB3ITGA2BACEPIN1CTSG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022265577-A2 | CORONAVIRUS ENZYME MODULATORS, METHODS OF SYNTHESIS AND USES THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2022-12-22 | — | — | WO | disclosed |
| WO-2022265577-A2 | CORONAVIRUS ENZYME MODULATORS, METHODS OF SYNTHESIS AND USES THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2022-12-22 | — | — | WO | disclosed |
| US-20070185060-A1 | Boronic acid thrombin inhibitors | TRIGEN LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| US-20070185060-A1 | Boronic acid thrombin inhibitors | TRIGEN LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| US-20070185060-A1 | Boronic acid thrombin inhibitors | TRIGEN LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| US-20060128613-A1 | Melanocortin receptor ligands | THE PROCTER & GAMBLE COMPANY | 2006-06-15 | — | — | US | disclosed |
| US-20050282757-A1 | Peptide boronic acid compounds useful in anticoagulation | TRIGEN LIMITED | 2005-12-22 | — | — | US | disclosed |
| US-20050282757-A1 | Peptide boronic acid compounds useful in anticoagulation | TRIGEN LIMITED | 2005-12-22 | — | — | US | disclosed |
| US-20050282757-A1 | Peptide boronic acid compounds useful in anticoagulation | TRIGEN LIMITED | 2005-12-22 | — | — | US | disclosed |
| WO-2005084687-A2 | BORONIC ACID THROMBIN INHIBITORS | TRIGEN LIMITED (GB) | 2005-09-15 | — | — | WO | disclosed |
| WO-2005084687-A2 | BORONIC ACID THROMBIN INHIBITORS | TRIGEN LIMITED (GB) | 2005-09-15 | — | — | WO | disclosed |
| CN-1571796-A | Melanocortin receptor ligands | PROCTER & GAMBLE (US) | 2005-01-26 | — | — | CN | disclosed |
| EP-1409540-A2 | MELANOCORTIN RECEPTOR LIGANDS | THE PROCTER & GAMBLE COMPANY (US) | 2004-04-21 | — | — | EP | disclosed |
| WO-2002026774-A2 | MELANOCORTIN RECEPTOR LIGANDS | THE PROCTER & GAMBLE COMPANY (US) | 2002-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128613-A1 | Melanocortin receptor ligands | MC3R, MC4R, MC1R | ITGB3 788/4885ITGA2B 2088/4885ACE 3224/4885 |
| US-20050282757-A1 | Peptide boronic acid compounds useful in anticoagulation | SERPINC1, HABP2, F11 | ITGB3 1478/4885ITGA2B 1324/4885ACE 1655/4885 |
| US-20070185060-A1 | Boronic acid thrombin inhibitors | F2, ECE1, BCAT1 | ITGB3 1337/4885ITGA2B 534/4885ACE 230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.